Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 817
- 试验地点
- 1
- 主要终点
- Reasons for Abstaining from Opioids Questionnaire
研究概览
简要总结
This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.
详细描述
The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must be 18 years of age or older.
- •Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
- •Participants must have a past or present opioid use disorder.
- •Participants must currently reside in the state of Massachusetts.
- •Participants must be able to comprehend the English language.
排除标准
- •Unable to complete an online survey.
- •Unable to complete a verification step that ensures bots are not used to complete survey.
- •Complete a survey with no variation suggesting they did not read the survey.
结局指标
主要结局
Reasons for Abstaining from Opioids Questionnaire
时间窗: Day 1
This 17-item scale will measure participant ratings of the importance of 17 factors that motivate abstinence from illicit drug use during office-based opioid treatment. Participants will be asked to rate each of these 17 items on a scale from 0 = "not at all important" to 4 = "extremely important."
Patients' Attitudes Toward the Use of Cannabis During Office-Based Opioid Treatment
时间窗: Day 1
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which they feel cannabis use is acceptable during office-based opioid treatment (OBOT), they believe that their prescribers' feel cannabis use is acceptable during OBOT, and they feel comfortable discussing cannabis use with their buprenorphine prescribers.
Patient's Experiences with Office-Based Opioid Treatment
时间窗: Day 1
This is an eight-item scale that measures the degree to which participants report being able to access buprenorphine treatment-related appointments and medications before and during the COVID-19 pandemic. Participants will be asked to rate each of the eight questions on a 7-point Likert scale from 1 = "extremely easy" to 7= "extremely difficult."
Patients' Attitudes Toward the Use of Cigarettes/E-Cigarettes During Office-Based Opioid Treatment
时间窗: Day 1
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which patients should be encouraged to quit smoking cigarettes and e-cigarette during office-based opioid treatment (OBOT) and the degree to which they feel smoking helps manage cravings during OBOT.
Patients' Attitudes Toward and Experiences with the Use of Benzodiazepines during Office-Based Opioid Treatment
时间窗: Day 1
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which benzodiazepine use is acceptable during office-based opioid treatment (OBOT), they feel OBOT providers find benzodiazepine use by their patients acceptable, and they feel comfortable openly discussing their benzodiazepine use with their buprenorphine prescriber.
次要结局
未报告次要终点